Diya Lahiri, pharmaceutical industry analyst, said: "The world rheumatoid arthritis treatments market will benefit from the entry of new drugs this decade. There are prominent needs in the RA market, the most important being the development of drugs that are truly disease modifying rather than merely symptom managing. R&D efforts will help develop novel treatments that will not only benefit patients but also help researchers understand rheumatoid arthritis better."
Visiongain forecasts that the rheumatoid arthritis drug market will expand steadily to 2021. The future of the market is promising, with increasing demand for novel treatments such as biological drugs. The prospect of newer, more-effective drugs for RA, such as anti-TNF agents, will help this market to grow further. This new study adds to visiongain's wide range of analytical reports in healthcare and other industry areas.
To view sample pages please visit http://www.visiongain.com/
For an exec summary please email Sara Peerun
Tel: +44 0207 3366100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@
# # #
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.